Welcome to our dedicated page for Immunovant news (Ticker: IMVT), a resource for investors and traders seeking the latest updates and insights on Immunovant stock.
Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage immunology company developing FcRn-targeting monoclonal antibodies for IgG-mediated autoimmune diseases. The news flow around IMVT reflects its focus on advancing its lead asset IMVT-1402 and its first-generation antibody batoclimab through multiple clinical programs and financing events.
On this page, readers can follow company-issued updates such as quarterly and annual financial results, where Immunovant reports research and development spending, general and administrative expenses, net loss and cash position. These releases often include details on the status of potentially registrational trials of IMVT-1402 in Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis and Sjögren’s disease, as well as a proof-of-concept trial in cutaneous lupus erythematosus.
News items also cover clinical data readouts. Immunovant has announced topline results from a Phase 3 study of batoclimab in myasthenia gravis and initial results from a Phase 2b study in CIDP, highlighting correlations between deeper IgG reductions and improved clinical outcomes. Additional communications describe six‑month off‑treatment remission data from a batoclimab proof‑of‑concept study in uncontrolled Graves’ disease and the design of IMVT‑1402 trials informed by these findings.
Investors can also see coverage of corporate developments, including leadership transitions, changes in board composition and strategic alignment with controlling stockholder Roivant Sciences Ltd. Capital markets updates, such as the pricing of a common stock financing with anticipated gross proceeds of approximately $550 million, are reported through news releases as well.
For anyone tracking IMVT, this news feed provides company-sourced information on clinical milestones, financial reporting, governance changes and equity offerings related to Immunovant’s autoimmune disease pipeline.
Immunovant (Nasdaq: IMVT) has announced an upcoming investor webcast scheduled for Wednesday, March 19, 2025, at 8:00 AM ET. The presentation will focus on revealing results from two significant clinical trials: the Phase 3 study of batoclimab in Myasthenia Gravis (MG) and initial findings from the Phase 2b study in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
The webcast will feature presentations from Pete Salzmann, M.D., MBA, Immunovant's Chief Executive Officer, alongside Matt Gline, Chief Executive Officer of Roivant. Interested participants can access the live webcast through registration, and it will also be available in the News & Events section of Immunovant's website. A replay option will be provided immediately after the event.
Immunovant (NASDAQ: IMVT) reported financial results for Q3 2024, highlighting significant progress in its clinical programs. The company has received clearance for six IND applications and initiated pivotal studies for IMVT-1402 in Graves' disease and difficult-to-treat rheumatoid arthritis using a 2.25ml autoinjector.
Key financial metrics include a pro forma cash balance of approximately $825 million as of December 31, 2024, including $450 million from a recent private placement. Q3 net loss increased to $111.1 million ($0.76 per share) compared to $51.4 million ($0.36 per share) in the previous year. R&D expenses rose to $94.5 million from $48.3 million year-over-year.
The company expects to release top-line results from the batoclimab trial in myasthenia gravis and initial results from the CIDP trial by March 31, 2025, with additional Graves' disease data expected in summer 2025.
Immunovant (Nasdaq: IMVT), a clinical-stage immunology company, announced a $450 million private placement. The company will sell 22,500,000 shares of common stock at $20.00 per share to three institutional accredited investors in a private investment in public equity (PIPE). The transaction is expected to close around January 15, 2025, subject to customary conditions.
The proceeds will be used to advance Immunovant's development pipeline, working capital, and other corporate purposes. Dr. Pete Salzmann, CEO of Immunovant, stated that the additional capital will support the development of their lead asset, IMVT-1402.
The shares sold in the PIPE are not registered under the Securities Act of 1933 and cannot be offered or sold in the U.S. without an exemption. However, Immunovant has agreed to register the resale of these shares with the SEC.
Immunovant (IMVT) reported key developments and financial results for Q2 2024. The company secured five IND clearances for its lead asset IMVT-1402 across various therapeutic areas. Plans include initiating 4-5 potentially registrational trials by March 2025, including programs in Graves' disease and difficult-to-treat rheumatoid arthritis. Financial highlights show cash position of $472.9M, with R&D expenses increasing to $97.3M from $48.0M YoY. Net loss widened to $109.1M ($0.74 per share) compared to $58.7M ($0.45 per share) in the prior year period.
Immunovant announced that data from their Phase 2a trial of batoclimab in Graves' disease will be presented at the 2024 American Thyroid Association Annual Meeting in Chicago. The late-breaking oral presentation will showcase new data on both thyroid-specific and extrathyroidal manifestations of Graves' disease. The presentation titled 'Efficacy and Safety of the FcRn Inhibitor, Batoclimab, in Graves' Thyroidal and Extrathyroidal Disease: a Proof-of-concept Study' will be delivered by Dr. George Kahaly on November 1, 2024.
Ankyra has appointed Dr. Julia G. Butchko and Ms. Tara Withington as independent board members, effective September 25, 2024. This brings the total board composition to seven directors. Dr. Butchko, with 25 years of industry experience, most recently served as Chief Development Officer at Immunovant (NASDAQ: IMVT). Ms. Withington has over 40 years of executive experience in the nonprofit sector and is currently a principal and Vice President with Executive Director, Incorporated (EDI).
Ankyra's lead asset, ANK-101, an anchored IL-12, has entered phase I clinical trials earlier this year. Over 10 patients with advanced solid cancers have been treated at multiple study sites in the United States and Canada (NCT:06171750).
Immunovant (Nasdaq: IMVT) reported positive results from its Phase 2a trial of batoclimab in Graves' Disease. Key findings include:
1. 76% response rate with high-dose batoclimab at week 12
2. 56% ATD-Free response rate at week 12
3. Strong correlation between IgG lowering and clinical outcomes
The company also announced FDA clearance for an IMVT-1402 pivotal trial in Graves' Disease, expected to start by year-end. Market research indicates 25-30% of Graves' Disease patients are uncontrolled on antithyroid drugs annually, representing a significant commercial opportunity. Immunovant believes these results validate the unmet medical need and demonstrate strong response rates in this population.
Immunovant (Nasdaq: IMVT) has announced an investor webcast scheduled for September 9, 2024, at 8:00 a.m. ET to provide updates on its Graves' Disease (GD) program. The presentation will cover:
- New epidemiologic data on the potential addressable market
- Additional results from the Phase 2 study of batoclimab
- An overview of the IMVT-1402 development program in GD
Investors can register for the event through a provided link, and a live webcast will be available on Immunovant's website. A replay of the event and presentation will be accessible immediately after the webcast concludes.
Immunovant (IMVT) reported progress in its clinical programs and financial results for Q1 FY2025 ended June 30, 2024. Key highlights include:
1. Completed enrollment in batoclimab pivotal Myasthenia Gravis (MG) trial
2. On track to initiate IMVT-1402 registrational program by March 31, 2025
3. Three IND applications for IMVT-1402 expected to be active by December 31, 2024
4. Cash position of $560 million as of June 30, 2024
5. R&D expenses increased to $75.5 million from $50.6 million YoY
6. Net loss of $87.2 million ($0.60 per share) compared to $73.9 million ($0.57 per share) YoY
The company aims to initiate 4-5 registrational programs for IMVT-1402 by March 2025 and clinical trials in 10 indications by March 2026.
Immunovant (Nasdaq: IMVT) reported corporate updates and financial results for the fourth quarter and fiscal year ended March 31, 2024.
The company plans to initiate 4-5 potentially registrational studies for its lead asset IMVT-1402 in various therapeutic areas by March 31, 2025. Topline data from the batoclimab Myasthenia Gravis study is expected in the same timeframe.
R&D expenses for Q4 increased to $66.1M, and net loss widened to $75.3M. For the fiscal year, R&D expenses rose to $212.9M, and net loss was $259.3M.
IMVT's cash position was approximately $635M as of March 31, 2024. They hold a new U.S. patent extending until June 2043.